VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada, US, RoW | DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys | ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP | HIV Infections | 10/25 | 10/26 | | |
NCT06741397: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M) |
|
|
| Not yet recruiting | 2 | 200 | US | CAB LA, New formulation of CAB LA | ViiV Healthcare | HIV Infections | 08/26 | 12/28 | | |
